Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46


Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.

J Clin Oncol. 2007 Mar 20;25(9):1027-32. Epub 2007 Feb 20.


Identification of pancreatic cancer stem cells.

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM.

Cancer Res. 2007 Feb 1;67(3):1030-7.


Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line.

Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA, Rosen JM.

J Cell Sci. 2007 Feb 1;120(Pt 3):468-77. Epub 2007 Jan 16.


Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.

Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. Epub 2007 Jan 8.


WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells.

Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM.

Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23. Epub 2007 Jan 3. Erratum in: Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7307.


The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.

Phillips TM, McBride WH, Pajonk F.

J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85.


Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity.

Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR.

Stem Cells. 2007 Mar;25(3):718-22. Epub 2006 Nov 16.


CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.

Breast Cancer Res. 2006;8(5):R59.


Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, Pajonk F.

J Clin Oncol. 2006 Oct 10;24(29):4708-13. Erratum in: J Clin Oncol. 2007 Apr 10;25(11):1457.


Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ.

Clin Cancer Res. 2006 Oct 1;12(19):5615-21.


Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin.

Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR.

Neurodegener Dis. 2006;3(1-2):94-100.


Erythropoietin or darbepoetin for patients with cancer.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003407. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD003407.


Notch-independent regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human endothelial cells.

Curry CL, Reed LL, Nickoloff BJ, Miele L, Foreman KE.

Lab Invest. 2006 Aug;86(8):842-52. Epub 2006 May 29.


Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC.

Neurology. 2006 Feb 28;66(4):602-4.


Prospective identification of tumorigenic prostate cancer stem cells.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ.

Cancer Res. 2005 Dec 1;65(23):10946-51.


A tumorigenic subpopulation with stem cell properties in melanomas.

Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M.

Cancer Res. 2005 Oct 15;65(20):9328-37.


Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.

J Clin Oncol. 2005 Sep 1;23(25):5960-72. Epub 2005 Aug 8.


Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG.

Cancer Res. 2005 Jul 1;65(13):5506-11.


Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin.

Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S, Chow TY.

Mol Cancer Ther. 2004 Dec;3(12):1525-32.


Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway.

Carvalho G, Lefaucheur C, Cherbonnier C, Métivier D, Chapel A, Pallardy M, Bourgeade MF, Charpentier B, Hirsch F, Kroemer G.

Oncogene. 2005 Jan 27;24(5):737-45.


Supplemental Content

Support Center